Tonix Pharmaceuticals has showcased compelling preclinical data for its single-dose mpox vaccine candidate TNX-801 at the World Vaccine Congress Washington 2025, highlighting significant potential for addressing global mpox outbreaks.
The company's research revealed that TNX-801, a minimally replicative live-virus vaccine, demonstrated robust protection against mpox and rabbitpox in animal studies. Notably, the vaccine provided durable immunity lasting up to six months and showed effectiveness in protecting both standard and immunocompromised subjects.
The vaccine's performance aligns with the World Health Organization's preferred target profile for mpox vaccines, suggesting potential broad applicability in current and future global health emergencies. This research represents a critical step toward developing a comprehensive solution for mpox prevention.
TNX-801's development is particularly significant given the recent global mpox outbreaks, which have underscored the need for effective vaccination strategies. By offering a single-dose approach with extended protection, the vaccine could provide a more convenient and efficient method of immunization compared to existing alternatives.
The preclinical data presented at the World Vaccine Congress demonstrates Tonix Pharmaceuticals' commitment to addressing public health challenges through innovative vaccine technologies. As the company continues to advance its research, TNX-801 represents a promising approach to combating infectious diseases.
